RTY-694 is a potent, orally active ABCB4/BSEP positive functional modulator ... rate of developing cholangiocarcinoma, a bile duct cancer, compared to the general population.

“These data continue to substantiate the potential of a dual-targeted ABCB4/BSEP PFM to address the dysfunction of these two membrane protein transporters and offer a differentiated approach to ...

Pol Boudes, M.D., Chief Medical Officer of Rectify, added “We believe our differentiated dual-targeted approach of addressing ABCB4 and BSEP ... a bile duct cancer, compared to the general ...